Clinically, Eze, a NPC1L1 inhibitor, is mainly used as a treatment for hypercholesterolemia; however, in addition to its lipid-lowering activity, several studies have reported that Eze may attenuate ischemic-related oxidative stress and inflammation [14, 19]. Here, NPC1L1 is linked to familial hypercholesterolemia.